![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim: to evaluate the associations between signatures of apoptotic endothelial cell-derived microvesicles (MVs) with phenotypes of chronic heart failure (HF). Methods: The study cohort consisted of 388 prospectively involved subjects with HF patients with predominantly reduced left ventricular ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with mid-range ejection fraction (HFmrEF). All biomarkers were measured at baseline. Results: The number of circulating CD31+/annexin V+ MVs in HFrEF and HFmrEF patients was similar. The number of circulating CD144+/annexin V+ MVs in HFrEF patients was significantly higher than HFmrEF and HFpEF. We determined that a combination of number of circulating CD31+/annexin V+ MVs and Gal-3 was the best predictor of HFpEF and that number of circulating CD144+/annexin V+ MVs is able to increase predictive capabilities of soluble ST2 (sST2) and Gal-3 for HFrEF. Conclusion: We found that the number of circulating CD31+/annexin V+ MVs may improve a predictive capacity for conventional HF biomarkers.
Author contributions
AE Berezin initiated the hypothesis and designed the study protocol; contributed to collect, analyze and interpret the data; performed statistical analysis; wrote the manuscript and approved the final version of the paper. AA Kremzer enrolled the patients; collected and analyzed the data; reviewed the source documents; performed flow cytometry technique and interpreted the obtained results. TA Samura performed echocardiography and interpreted the obtained results. TA Berezina contributed to enroll the patients in the study and collected the data. All authors read the manuscript before submitting and agree with final version of the paper.
Acknowledgements
The authors thank all patients for their participation in the investigation, staff of the Regional Zaporozhye Hospital (Ukraine) and the doctors, nurses and administrative staff in City hospital 6 (Zaporozhye, Ukraine), Regional Hospital (Zaporozhye, Ukraine), Regional Center of Cardiovascular Diseases (Zaporozhye, Ukraine), Private Hospital ‘Vita Center’ (Zaporozhye, Ukraine), Central Clinical and Immunology Laboratory ‘Dia-Service’ (Zaporozhye, Ukraine), general practices and site-managed organizations that assisted the study.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Ethical conduct of research
All the patients have given their written informed consent for participation in the study. The study was approved by Local Ethical Committee (IRB # 3/2010) of State Medical University of Zaporozhye (Ukraine). The authors state that they have obtained appropriate institutional review board approval (IRB # 3/2010, State Medical University of Zaporozhye, Ukraine). The investigators followed strictly all the requirements to clinical trials in conformity with the World Medical Association Declaration of Helsinki, 1964, good clinical practice proveided by International Conference on Harmonization, Council of Europe Convention for the Protection of Human Rights and Dignity of the Human Being in view of using achievements in biology and medicine, convention on Human Rights and Biomedicine, including Additional Protocol to the Convention on Human Rights and Biomedicine, concerning Biomedical Research, and legislation of Ukraine. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.